VectivBio Holding AG
VectivBio Holding AG Stock, NASDAQ:VECT
VectivBio Holding AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.